Table 1.
Summarised clinical features of pyomyositis in systemic lupus erythaematosus
| Reference/year | Age (year) | Current therapy | Location(s) | Organism(s) | Outcome |
|---|---|---|---|---|---|
| Ushijima et al4/1985 | 14 | PRDL | Glutaeal, quadriceps | S. aureus | Recovery |
| Shames and Fast5/1989 | 59 | PRED | Gluteal | S. aureus | Recovery |
| Shamiss et al6/1990 | 19 | Steroid | Posterior thighs, calves | Salmonella enteritidis | Recovery |
| Bonafede et al7/1992 | 31 | None | Upper arm, thigh | S. aureus | Recovery |
| Dede et al8/1993 | 23 | PRDL+CTX | Calf | S. aureus | Recovery |
| Yoshino et al9/1994 | 44 | MePRDL | Glutaeal | S. aureus | Recovery |
| Belzunegui et al10/1995 | 27 | PRED+CTX | Erector spinae | M. tuberculosis | Recovery |
| Gordon et al11/1995 | 48 | Steroid | Pectoralis major and minor, subclavius, intercostal muscles | S. aureus | Death |
| Claudepierre et al12/1996 | 32 | PRED+HCQ | Quadriceps | S. aureus | Recovery |
| Ushida et al13/2001 | 21 | PRDL+MZR | Psoas | S. aureus | Death |
| Teh et al14/2002 | 25 | PRDL+MMF | Thigh, calf | M. haemophilum | Recovery |
| García Hernández et al15/2003 | 33 | None | Iliopsoas | S. aureus | Recovery |
| Jidpugdeebodin and Punyagupta16/2004 | 31 | PRDL+CTX+MePRDL | Shoulder, axilla, arm, forearm | Salmonella serogroup B | Recovery |
| Ravindran and Duke17/2009 | 34 | HCQ | Pronator teres | S. aureus | Recovery |
| Collier et al18/2010 | NA | PRDL | Sternocleidomastoid | NA* | Recovery |
| El Baaj et al19/2010 | 47 | PRED+HCQ | Quadriceps | E. coli | Recovery |
| Manzoor20/2010 | 23 | NA | Rectus femoris | S. aureus | Recovery |
| Sokolove et al21/2010 | 39 | PRED | Quadriceps | M. tuberculosis | Recovery |
| Souza et al22/2011 | 25 | NA | Iliacus | S. aureus | Recovery |
| Blay et al23/2014 | 16 | PRED+HCQ+AZA | Vastus intermedius | NA† | Recovery |
| Chebbi et al24/2014 | 52 | PRDL+HCQ+MMF | Iliacus, glutaeal | S. aureus | Recovery |
| Simopoulou et al25/2014 | 46 | PRDL | Vastus lateralis | S. aureus and M. tuberculosis | Recovery |
| Present case/2016 | 14 | PRDL | Gastrocnemius | K. pneumoniae | Recovery |
*The patient's condition was improved by treatment with benzylpenicillin given at 2.4 g 4 times per day.
†The patient responded well to clindamycin plus intravenous cefepime for 1 week and oral clindamycin for an additional week.
AZA, azathioprine; CTX, cyclophosphamide; E. coli, Escherichia coli; HCQ, hydroxychloroquine; K. pneumoniae, Klebsiella pneumoniae; MePRDL, methylprednisolone; M. haemophilum, Mycobacterium haemophilum; M.tuberculosis, Mycobacterium tuberculosis; MMF, mycophenolate mofetil; MZR, mizoribine; NA, not available; PRDL, prednisolone; PRED, prednisone; S. aureus, Staphylococcus aureus.